148 related articles for article (PubMed ID: 35020071)
21. G-protein-coupled estrogen receptor GPR30 and tamoxifen resistance in breast cancer.
Ignatov A; Ignatov T; Weissenborn C; Eggemann H; Bischoff J; Semczuk A; Roessner A; Costa SD; Kalinski T
Breast Cancer Res Treat; 2011 Jul; 128(2):457-66. PubMed ID: 21607586
[TBL] [Abstract][Full Text] [Related]
22. Raptor localization predicts prognosis and tamoxifen response in estrogen receptor-positive breast cancer.
Bostner J; Alayev A; Berman AY; Fornander T; Nordenskjöld B; Holz MK; Stål O
Breast Cancer Res Treat; 2018 Feb; 168(1):17-27. PubMed ID: 29128895
[TBL] [Abstract][Full Text] [Related]
23. Network-based approach to identify prognostic biomarkers for estrogen receptor-positive breast cancer treatment with tamoxifen.
Liu R; Guo CX; Zhou HH
Cancer Biol Ther; 2015; 16(2):317-24. PubMed ID: 25756514
[TBL] [Abstract][Full Text] [Related]
24. The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model.
Long BJ; Jelovac D; Thiantanawat A; Brodie AM
Clin Cancer Res; 2002 Jul; 8(7):2378-88. PubMed ID: 12114443
[TBL] [Abstract][Full Text] [Related]
25. Tamoxifen through GPER upregulates aromatase expression: a novel mechanism sustaining tamoxifen-resistant breast cancer cell growth.
Catalano S; Giordano C; Panza S; Chemi F; Bonofiglio D; Lanzino M; Rizza P; Romeo F; Fuqua SA; Maggiolini M; Andò S; Barone I
Breast Cancer Res Treat; 2014 Jul; 146(2):273-85. PubMed ID: 24928526
[TBL] [Abstract][Full Text] [Related]
26. The anti-proliferative effect of suramin towards tamoxifen-sensitive and resistant human breast cancer cell lines in relation to expression of receptors for epidermal growth factor and insulin-like growth factor-I: growth stimulation in the presence of tamoxifen.
Boylan M; van den Berg HW; Lynch M
Ann Oncol; 1998 Feb; 9(2):205-11. PubMed ID: 9553667
[TBL] [Abstract][Full Text] [Related]
27. Farnesoid X receptor inhibits tamoxifen-resistant MCF-7 breast cancer cell growth through downregulation of HER2 expression.
Giordano C; Catalano S; Panza S; Vizza D; Barone I; Bonofiglio D; Gelsomino L; Rizza P; Fuqua SA; Andò S
Oncogene; 2011 Sep; 30(39):4129-40. PubMed ID: 21499302
[TBL] [Abstract][Full Text] [Related]
28. A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer.
Nielsen TO; Parker JS; Leung S; Voduc D; Ebbert M; Vickery T; Davies SR; Snider J; Stijleman IJ; Reed J; Cheang MC; Mardis ER; Perou CM; Bernard PS; Ellis MJ
Clin Cancer Res; 2010 Nov; 16(21):5222-32. PubMed ID: 20837693
[TBL] [Abstract][Full Text] [Related]
29. Cyclin D-1, interleukin-6, HER-2/neu, transforming growth factor receptor-II and prediction of relapse in women with early stage, hormone receptor-positive breast cancer treated with tamoxifen.
Muss HB; Bunn JY; Crocker A; Plaut K; Koh J; Heintz N; Rincon M; Weaver DL; Tam D; Beatty B; Kaufman P; Donovan M; Verbel D; Weiss L
Breast J; 2007; 13(4):337-45. PubMed ID: 17593037
[TBL] [Abstract][Full Text] [Related]
30. FGFR1 Is Associated With Tamoxifen Resistance and Poor Prognosis of ER-Positive Breast Cancers by Suppressing ER Protein Expression.
Lv Q; Guan S; Zhu M; Huang H; Wu J; Dai X
Technol Cancer Res Treat; 2021; 20():15330338211004935. PubMed ID: 33783288
[TBL] [Abstract][Full Text] [Related]
31. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
[TBL] [Abstract][Full Text] [Related]
32. Global characterization of signalling networks associated with tamoxifen resistance in breast cancer.
Browne BC; Hochgräfe F; Wu J; Millar EK; Barraclough J; Stone A; McCloy RA; Lee CS; Roberts C; Ali NA; Boulghourjian A; Schmich F; Linding R; Farrow L; Gee JM; Nicholson RI; O'Toole SA; Sutherland RL; Musgrove EA; Butt AJ; Daly RJ
FEBS J; 2013 Nov; 280(21):5237-57. PubMed ID: 23876235
[TBL] [Abstract][Full Text] [Related]
33. Cytoplasmic accumulation of the RNA binding protein HuR is central to tamoxifen resistance in estrogen receptor positive breast cancer cells.
Hostetter C; Licata LA; Witkiewicz A; Costantino CL; Yeo CJ; Brody JR; Keen JC
Cancer Biol Ther; 2008 Sep; 7(9):1496-506. PubMed ID: 18769129
[TBL] [Abstract][Full Text] [Related]
34. PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients.
Beelen K; Opdam M; Severson TM; Koornstra RH; Vincent AD; Wesseling J; Muris JJ; Berns EM; Vermorken JB; van Diest PJ; Linn SC
Breast Cancer Res; 2014 Jan; 16(1):R13. PubMed ID: 24467828
[TBL] [Abstract][Full Text] [Related]
35. Amplified in breast cancer 1 in human epidermal growth factor receptor - positive tumors of tamoxifen-treated breast cancer patients.
Kirkegaard T; McGlynn LM; Campbell FM; Müller S; Tovey SM; Dunne B; Nielsen KV; Cooke TG; Bartlett JM
Clin Cancer Res; 2007 Mar; 13(5):1405-11. PubMed ID: 17332282
[TBL] [Abstract][Full Text] [Related]
36. Resistance to tamoxifen-induced apoptosis is associated with direct interaction between Her2/neu and cell membrane estrogen receptor in breast cancer.
Chung YL; Sheu ML; Yang SC; Lin CH; Yen SH
Int J Cancer; 2002 Jan; 97(3):306-12. PubMed ID: 11774281
[TBL] [Abstract][Full Text] [Related]
37. In situ aromatase expression in primary tumor is associated with estrogen receptor expression but is not predictive of response to endocrine therapy in advanced breast cancer.
Lykkesfeldt AE; Henriksen KL; Rasmussen BB; Sasano H; Evans DB; Møller S; Ejlertsen B; Mouridsen HT
BMC Cancer; 2009 Jun; 9():185. PubMed ID: 19531212
[TBL] [Abstract][Full Text] [Related]
38. Aberrant fatty acid profile and FFAR4 signaling confer endocrine resistance in breast cancer.
Chu X; Zhou Q; Xu Y; Jiang J; Li Q; Zhou Q; Wu Q; Jin M; Wang H; Gu Y; Wang X; Wang B; He S; He X; Wu C; Zhang F; Zhang Y
J Exp Clin Cancer Res; 2019 Feb; 38(1):100. PubMed ID: 30795784
[TBL] [Abstract][Full Text] [Related]
39. The forkhead transcription factor FOXM1 promotes endocrine resistance and invasiveness in estrogen receptor-positive breast cancer by expansion of stem-like cancer cells.
Bergamaschi A; Madak-Erdogan Z; Kim YJ; Choi YL; Lu H; Katzenellenbogen BS
Breast Cancer Res; 2014 Sep; 16(5):436. PubMed ID: 25213081
[TBL] [Abstract][Full Text] [Related]
40. Overexpression of c-Myc and Bcl-2 during progression and distant metastasis of hormone-treated breast cancer.
Planas-Silva MD; Bruggeman RD; Grenko RT; Smith JS
Exp Mol Pathol; 2007 Feb; 82(1):85-90. PubMed ID: 17046747
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]